Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381393 | 1.00 | PTPN1 (0.42) | PTPN1NR1H2NR1H3PDE4BLMNA | |
| SCHEMBL31239015 | 0.91 | MAPK1 (0.38) | PTPN1NR1H2NR1H3LMNANPSR1 | |
| SCHEMBL24645524 | 0.85 | PTPN1 (0.42) | PTPN1NR1H2NR1H3PDE4BLMNA | |
| SCHEMBL18435493 | 0.85 | PTPN1 (0.42) | PTPN1NR1H2NR1H3PDE4BLMNA | |
| SCHEMBL18400274 | 0.85 | PTPN1 (0.42) | PTPN1NR1H2NR1H3PDE4BLMNA | |
| SCHEMBL12295992 | 0.85 | NPC1 (0.36) | PTPN1NR1H2LMNANPSR1CYP1A2 | |
| SCHEMBL2379580 | 0.85 | HSD17B10 (0.38) | PTPN1NR1H2LMNANPSR1CYP1A2 | |
| SCHEMBL2379577 | 0.85 | HSD17B10 (0.38) | PTPN1NR1H2LMNANPSR1CYP1A2 | |
| SCHEMBL27017483 | 0.84 | PTPN1 (0.41) | PTPN1NR1H2NR1H3PDE4BLMNA | |
| SCHEMBL2381284 | 0.83 | PTPN1 (0.41) | PTPN1NR1H2NR1H3PDE4BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729077-B2 | Anti-viral compounds, compositions, and methods of use | GLAXOSMITHKLINE LLC (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130310427-A1 | INHIBITORS OF HCV NS5A PROTEIN | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2580209-A2 | INHIBITORS OF HCV NS5A PROTEIN | Presidio Pharmaceuticals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011156543-A2 | INHIBITORS OF HCV NS5A PROTEIN | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| US-20110224211-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | GLAXOSMITHKLINE LLC | 2011-09-15 | — | — | US | disclosed |
| WO-2010062821-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310427-A1 | INHIBITORS OF HCV NS5A PROTEIN | HAVCR2, EIF2AK2, PPP2CA | PTPN1 190/4885NR1H2 2005/4885NR1H3 2074/4885 |
| US-20110224211-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | HAVCR2, SARS1, MAVS | PTPN1 2134/4885NR1H2 1821/4885NR1H3 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.